CenterBook Partners LP Sells 149,734 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

CenterBook Partners LP cut its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 17.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 717,275 shares of the company's stock after selling 149,734 shares during the quarter. CenterBook Partners LP owned approximately 0.67% of MaxCyte worth $1,958,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of MXCT. Gagnon Securities LLC increased its position in shares of MaxCyte by 431.3% during the first quarter. Gagnon Securities LLC now owns 1,048,318 shares of the company's stock valued at $2,862,000 after buying an additional 850,992 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of MaxCyte by 2.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 299,734 shares of the company's stock valued at $818,000 after purchasing an additional 7,754 shares in the last quarter. Moors & Cabot Inc. increased its holdings in shares of MaxCyte by 34.4% in the first quarter. Moors & Cabot Inc. now owns 17,708 shares of the company's stock worth $48,000 after purchasing an additional 4,528 shares during the period. Royce & Associates LP increased its holdings in shares of MaxCyte by 30.1% in the first quarter. Royce & Associates LP now owns 1,040,873 shares of the company's stock worth $2,842,000 after purchasing an additional 241,000 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of MaxCyte in the first quarter worth $143,000. Hedge funds and other institutional investors own 68.81% of the company's stock.

MaxCyte Stock Performance

MaxCyte stock traded up $0.03 during mid-day trading on Thursday, hitting $2.15. 436,760 shares of the company traded hands, compared to its average volume of 759,965. MaxCyte, Inc. has a one year low of $2.00 and a one year high of $5.20. The stock has a market cap of $228.79 million, a price-to-earnings ratio of -5.37 and a beta of 1.23. The stock has a fifty day moving average price of $2.23 and a 200-day moving average price of $3.11.

MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.10). The company had revenue of $10.39 million during the quarter, compared to the consensus estimate of $9.05 million. MaxCyte had a negative net margin of 110.92% and a negative return on equity of 19.90%. Sell-side analysts predict that MaxCyte, Inc. will post -0.42 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded MaxCyte from a "sell" rating to a "hold" rating in a research note on Sunday, June 8th.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.